TCGA-BH-A18P-01A-11R-A12D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 31
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.470
- PROTEIN_SECRETION+0.400
- MITOTIC_SPINDLE+0.390
- E2F_TARGETS+0.320
- NOTCH_SIGNALING+0.300
- UV_RESPONSE_DN+0.280
- TGF_BETA_SIGNALING+0.250
- PI3K_AKT_MTOR_SIGNALING+0.210
- ANDROGEN_RESPONSE+0.190
- MYC_TARGETS_V1+0.160
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.440
- ESTROGEN_RESPONSE_EARLY-0.390
- ESTROGEN_RESPONSE_LATE-0.380
- OXIDATIVE_PHOSPHORYLATION-0.350
- MYC_TARGETS_V2-0.340
- COAGULATION-0.270
- XENOBIOTIC_METABOLISM-0.260
- HYPOXIA-0.250
- INTERFERON_ALPHA_RESPONSE-0.240
- KRAS_SIGNALING_DN-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030972_D1.RNA-Seq | EPN | Supratentorial EPN | 0.796 |
| 2 | MDT-AP-3329 | Med | Medulloblastoma | 0.786 |
| 3 | ERR2598089 | fetal | fetal | 0.767 |
| 4 | AUR-AG0M-TTP1-A-2-0-R-A741-41 | — | D | 0.756 |
| 5 | TCGA-A7-A26I-01A-11R-A169-07 | — | E | 0.753 |
| 6 | MDT-AP-3311 | Med | Medulloblastoma | 0.737 |
| 7 | 0918cbd5-edd0-41c8-8b67-677f35ad4611 | — | — | 0.729 |
| 8 | MNG642 | — | — | 0.725 |
| 9 | SRR650203 | — | — | 0.721 |
| 10 | ERR2598094 | fetal | fetal | 0.719 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |